drugset / Trial / NCT03400098
ATTR Expanded Access Program (EAP) by Ionis
Summary
The purpose of this program is to provide expanded access to Inotersen for up to 100 Patients with Hereditary Transthyretin Amyloidosis (hTTR).
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inotersen | Antisense oligonucleotide | — | Subcutaneous |